Featured Research

from universities, journals, and other organizations

Aspirin use associated with lower risk of cancer death for men with prostate cancer

Date:
October 25, 2010
Source:
American Society for Radiation Oncology
Summary:
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study to be presented Nov. 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

"Evidence has shown that anticoagulants may interfere with cancer growth and spread," Kevin Choe, M.D., Ph.D., lead author of the study and a radiation oncologist at University of Texas Southwestern Medical School in Dallas, said. "If the major effect of anticoagulants is preventing metastasis (the ability of cancer cells to spread to other parts of the body), this may be why previous clinical trials with anticoagulation medications produced mixed results, since most patients in these trials already had metastasis. If the cancer has already metastasized, then anticoagulants may not be as beneficial."

Researchers evaluated data from the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) database to investigate the effect of anticoagulation medications (aspirin, warfarin, clopidogrel and/or enoxaparin) on the risk of dying from prostate cancer among men whose cancer has not metastasized.

The study involved 5,275 men whose cancer had not spread beyond the prostate gland (localized prostate cancer) and were treated with surgery or radiation, two of the most common treatment modalities for prostate cancer. Of these patients, 1,982 were taking anticoagulants. Patients were classified as having high-, intermediate- or low-risk disease.

Results of the study show that the use of anticoagulants among prostate cancer patients treated with either surgery or radiation reduced the risk of dying from the disease from 10 percent to 4 percent at 10 years. The risk of developing bone metastasis was also reduced. In addition, findings reveal that the benefit appeared even greater among patients diagnosed with high-risk prostate cancer. This is exciting news as patients with high-risk disease have the most aggressive cancer, with a high likelihood of dying from the disease, and the treatment options are currently limited.

The study also found that the benefit was most prominent with aspirin, compared to other anticoagulants.

Choe said, "Findings from this study are promising, however, further studies are necessary before the addition of aspirin to prostate cancer therapy becomes standard treatment."


Story Source:

The above story is based on materials provided by American Society for Radiation Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society for Radiation Oncology. "Aspirin use associated with lower risk of cancer death for men with prostate cancer." ScienceDaily. ScienceDaily, 25 October 2010. <www.sciencedaily.com/releases/2010/10/101025133750.htm>.
American Society for Radiation Oncology. (2010, October 25). Aspirin use associated with lower risk of cancer death for men with prostate cancer. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2010/10/101025133750.htm
American Society for Radiation Oncology. "Aspirin use associated with lower risk of cancer death for men with prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2010/10/101025133750.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins